Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells

被引:64
|
作者
Choudhury, Aniruddha [3 ]
Derkow, Katja [3 ]
Daneshmanesh, Amir Hossein [3 ]
Mikaelsson, Eva [3 ]
Kiaii, Shahryar [3 ]
Kokhaei, Parviz [3 ]
Osterborg, Anders [1 ,2 ,3 ]
Mellstedt, Hakan [1 ,2 ,3 ]
机构
[1] Karolinska Univ Hosp Solna, Dept Oncol, SE-17176 Stockholm, Sweden
[2] Karolinska Univ Hosp Solna, Dept Haematol, SE-17176 Stockholm, Sweden
[3] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
关键词
ROR1; FMOD; siRNA; apoptosis; chronic lymphocytic leukaemia; silencing; CHRONIC LYMPHOCYTIC-LEUKEMIA; RECEPTOR TYROSINE KINASE; GROWTH-FACTOR-BETA; AUTOLOGOUS T-LYMPHOCYTES; B-CELLS; MATRIX PROTEIN; EXPRESSION; FIBROMODULIN; GENE; DECORIN;
D O I
10.1111/j.1365-2141.2010.08362.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P>We have previously demonstrated that ROR1 and FMOD (fibromodulin) are two genes upregulated in chronic lymphocytic leukaemia (CLL) cells compared to normal blood B cells. In this study, siRNAs were used to specifically silence ROR1 and FMOD expression in CLL cells, healthy B cells and human fibroblast cell lines. siRNA treatment induced a specific reduction (75-95%) in FMOD and ROR1 mRNA. Western blot analysis with specific antibodies for FMOD and ROR1 demonstrated that the proteins were significantly downregulated 48 h after siRNA treatment. Silencing of FMOD and ROR1 resulted in statistically significant (P < 0.05-0.001) apoptosis of CLL cells but not of B cells from normal donors. Human fibroblast cell lines treated with FMOD and ROR1 siRNA did not undergo apoptosis. This is the first report demonstrating that ROR1 and FMOD may be involved in the survival of CLL cells. ROR1 in particular is further explored as potential target for therapy in CLL.
引用
收藏
页码:327 / 335
页数:9
相关论文
共 50 条
  • [21] ROR1 promotes the proliferation of endometrial cancer cells
    Zhang, Huilin
    Yan, Xiaofang
    Ke, Jieqi
    Zhang, Yongli
    Dai, Chenyun
    Zhu, Mei
    Jiang, Feizhou
    Wan, Xiaoping
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (10): : 10603 - 10610
  • [22] T Cells From CLL Patients Recognize Spontaneously Peptides Derived of the Receptor Tyrosine Kinase Ror1
    Hojjat-Farsangi, Mohammad
    Daneshmanesh, Amir Hossein
    Jeddi-Tehrani, Mahmood
    Osterborg, Anders
    Shokri, Fazel
    Mellstedt, Hakan
    Rabbani, Hodjattallah
    [J]. BLOOD, 2010, 116 (21) : 1483 - 1483
  • [23] Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells
    Hojjat-Farsangi, Mohammad
    Ghaderi, Amineh
    Daneshmanesh, AmirHossein
    Lehto, Jemina
    Moshfegh, Ali
    Kokhaei, Parviz
    Vagberg, Jan
    Olsson, Elisabeth
    Lofberg, Charlotta
    Norstrom, Charlotta Carina
    Schultz, Johan
    Norin, Martin
    Olin, Thomas
    Drakos, Elias
    Rassidakis, George Z.
    Osterborg, Anders
    Mellstedt, Hakan
    [J]. BLOOD, 2019, 134
  • [24] RETRACTED: Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells (Retracted article. See vol. 17, 2022)
    Hojjat-Farsangi, Mohammad
    Ghaemimanesh, Fatemeh
    Daneshmanesh, Amir Hossein
    Bayat, Ali-Ahmad
    Mahmoudian, Jafar
    Jeddi-Tehrani, Mahmood
    Rabbani, Hodjatallah
    Mellstedt, Hakan
    [J]. PLOS ONE, 2013, 8 (04):
  • [25] ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells
    Ghaderi, Amineh
    Daneshmanesh, Amir Hossein
    Moshfegh, Ali
    Kokhaei, Parviz
    Vagberg, Jan
    Schultz, Johan
    Olin, Thomas
    Harrysson, Sara
    Smedby, Karin E.
    Drakos, Elias
    Rassidakis, Georgios Z.
    Osterborg, Anders
    Mellstedt, Hakan
    Hojjat-Farsangi, Mohammad
    [J]. BIOMEDICINES, 2020, 8 (06)
  • [26] Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis
    Henry, Claire
    Hacker, Neville
    Ford, Caroline
    [J]. ONCOTARGET, 2017, 8 (68) : 112727 - 112738
  • [27] RETRACTION: Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells (Retraction of Vol 8, art no E61167, 2013)
    Hojjat-Farsangi, M.
    Ghaemimanesh, F.
    Daneshmanesh, A. H.
    Bayat, A-A
    Mahmoudian, J.
    Jeddi-Tehrani, M.
    [J]. PLOS ONE, 2022, 17 (05):
  • [28] Characterization of Peripheral B Cells Expressing CLL-Associated Receptor Tyrosine Kinase ROR1 in Healthy Donors
    Milleck, Julia
    Kreuzer, Karl-Anton
    Assenmacher, Mario
    Schmitz, Juergen
    Jaehn, Peter S.
    [J]. BLOOD, 2012, 120 (21)
  • [29] Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells
    Miyake, Noriko
    Ochi, Nobuaki
    Yamane, Hiromichi
    Fukazawa, Takuya
    Ikeda, Tomoko
    Yokota, Etsuko
    Takeyama, Masami
    Nakagawa, Nozomu
    Nakanishi, Hidekazu
    Kohara, Hiroyuki
    Nagasaki, Yasunari
    Kawahara, Tatsuyuki
    Ichiyama, Naruhiko
    Yamatsuji, Tomoki
    Naomoto, Yoshio
    Takigawa, Nagio
    [J]. LUNG CANCER, 2020, 139 : 170 - 178
  • [30] Novel ROR1 Antibody Is Able to Trigger Specific and Superior Complement-Dependent Cytotoxicity (CDC) on Primary CLL Cells
    Paredes-Moscosso, Solange R.
    Della Peruta, Marco
    Gohil, Satyen Harish
    Harrasser, Micaela
    Nathwani, Amit C.
    [J]. BLOOD, 2016, 128 (22)